Q28134897 | high-grade serous carcinoma |
Q123750979 | low-grade serous carcinoma |
Q18553575 | ovarian serous carcinoma |
Q7455060 | serous cystadenocarcinoma |
Q44049813 | "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer |
Q94095229 | 2317 Uterine serous carcinoma is associated with a high risk of venous thromboembolism regardless of latency from surgical staging |
Q90939662 | A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? |
Q89752152 | A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy |
Q30489669 | A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma |
Q92336127 | A Comprehensive Review of Ovarian Serous Carcinoma |
Q108589263 | A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis |
Q91470904 | A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma |
Q98501449 | A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles from Culture Supernatant of Human Ovarian Cancer Cell Line A2780 and Body Fluids of High-Grade Serous Carcinoma Patients |
Q85112334 | A Unique case of primary squamous carcinoma of the salpinx associated with serous carcinoma of the omentum: a pathological and molecular study |
Q35980522 | A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006 |
Q33264156 | A candidate precursor to serous carcinoma that originates in the distal fallopian tube. |
Q42045828 | A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination |
Q67387730 | A case of ovarian papillary serous carcinoma of low malignant potential |
Q37651338 | A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference? |
Q48344395 | A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. |
Q36138088 | A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer |
Q34111959 | A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. |
Q28295789 | A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary |
Q40205750 | A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model |
Q92041750 | A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC) |
Q33347156 | A pilot study of topotecan in the treatment of serous carcinoma of the uterus |
Q36737086 | A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. |
Q89568510 | A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma |
Q36520687 | A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome |
Q92609149 | A successfully treated primary peritoneal carcinosarcoma and serous carcinoma of stage IIIC rescued from hypovolemic shock due to tumor rupture |
Q34387999 | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
Q82293644 | A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases |
Q92416619 | ADNP (Activity Dependent Neuroprotector Homeobox): A novel oncogene driving poor prognosis in high-grade serous carcinoma |
Q88072881 | APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival |
Q85655227 | AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma |
Q41970635 | Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report |
Q83986440 | Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? |
Q90387906 | Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma |
Q58080932 | Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial |
Q81574394 | Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma |
Q97517002 | Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium |
Q67974898 | Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma |
Q50225470 | Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come |
Q35887356 | Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combination chemotherapy |
Q37676705 | Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis |
Q36696435 | Alpha-fetoprotein-producing serous carcinoma of the uterus metastasizing to the ovaries, mimicking primary ovarian yolk sac tumor: a case report and review of the literature |
Q38297206 | Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma |
Q40115732 | Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. |
Q36341198 | Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival |
Q34899256 | Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma |
Q38625315 | An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience |
Q80337829 | An unusual composite endometrial tumor combining papillary serous carcinoma and small cell carcinoma |
Q43284687 | An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). |
Q61898793 | Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study |
Q64262530 | Anaphylaxis Induced by Sugammadex in a Patient with Papillary Serous Carcinoma of the Uterine Adnexa Undergoing Exploratory Laparotomy |
Q94591600 | Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells? |
Q90672793 | Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report |
Q88640647 | Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC) |
Q50964902 | Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. |
Q92950797 | Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma |
Q35840413 | Association between uterine serous carcinoma and breast cancer |
Q85327489 | Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance |
Q52431522 | Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. |
Q91709261 | Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models |
Q33992783 | Axillary metastasis from an occult tubal serous carcinoma in a patient with ipsilateral breast carcinoma: a potential diagnostic pitfall |
Q40523803 | B7-H4 expression in ovarian serous carcinoma: a study of 306 cases |
Q59125630 | BET inhibitors: Betting on improved outcomes in uterine serous carcinoma |
Q91994058 | BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma |
Q77385661 | BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum |
Q38403255 | BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines |
Q73574334 | BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis |
Q33832014 | Bilateral Primary Papillary Serous Carcinoma of the Fallopian Tube |
Q51781362 | Bilateral micropapillary serous carcinoma of the ovary: a case report. |
Q36801308 | Bilateral primary fallopian tube papillary serous carcinoma in postmenopausal woman: Report of two cases |
Q51107512 | Bilateral synchronous high-grade serous carcinoma and clear cell carcinoma in right and left ovaries with immunohistochemical confirmation: an exceptional finding. |
Q84218716 | Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites |
Q92845245 | Bleeding and bowel obstruction in giant ovarian serous carcinoma - a video vignette |
Q35614139 | Brain metastasis from uterine serous carcinoma: A case report and review of literature |
Q36039847 | Brain metastasis in two patients with stage IA papillary serous carcinoma of the uterus |
Q90964269 | Breast metastases: A rare manifestation of advanced uterine serous carcinoma |
Q74519472 | CA 125 may not reflect disease status in patients with uterine serous carcinoma |
Q69684182 | CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma |
Q42365333 | CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance |
Q51536234 | CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. |
Q76892093 | CONSIDERATIONS AND ANATOMO-CLINICAL OBSERVATIONS ON SEROUS CARCINOMA OF THE OVARY |
Q47141255 | CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity |
Q77186620 | CT appearance of primary papillary serous carcinoma of the peritoneum |
Q38367063 | CT features of low grade serous carcinoma of the ovary |
Q44261967 | Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases |
Q64091838 | Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)? |
Q89350027 | Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma |
Q26998068 | Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma |
Q47588829 | Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. |
Q102214462 | Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma |
Q92025518 | Case of a Sister Mary Joseph's Nodule in a High Grade Serous Carcinoma |
Q87414046 | Case of uterine papillary serous carcinoma following tamoxifen treatment that could not be diagnosed during screening |
Q91590494 | Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma |
Q84016865 | Cervical metastasis as the first manifestation of ovarian papillary serous carcinoma |
Q92293438 | Characteristics and prognostic significance of incidentally detected cancer cells in uterine specimens of patients with pelvic high-grade serous carcinoma |
Q57297686 | Characterization of Risk Factors and Timing of Venous Thromboembolism in Patients With Uterine Serous Carcinoma |
Q98499784 | Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma |
Q92714424 | Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma |
Q35519808 | Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma |
Q68384787 | Chemotherapeutic approach to uterine papillary serous carcinoma |
Q89902069 | Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy |
Q42938103 | Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment |
Q81571883 | Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma |
Q79918669 | Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma |
Q39167159 | Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone |
Q83422587 | Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial |
Q77719756 | Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma |
Q89529848 | Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma |
Q33912347 | Clinical Relevance of Increased Endothelial and Mesothelial Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with Metastatic Ovarian High-Grade Serous Carcinoma |
Q30278404 | Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp |
Q64115689 | Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers |
Q44043688 | Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study |
Q45353174 | Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen |
Q35575176 | Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. |
Q81257215 | Clinical significance of Her-2/neu overexpression in uterine serous carcinoma |
Q81797649 | Clinico-cytological study of uterine papillary serous carcinoma |
Q44231450 | Clinico-pathological study of uterine papillary serous carcinoma |
Q92168383 | Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma |
Q42774141 | Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy |
Q92248873 | Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma |
Q59135515 | Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases |
Q35007178 | Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma |
Q95938188 | Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma |
Q84380481 | Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival |
Q37122620 | Coexistence of tuberculous peritonitis and primary papillary serous carcinoma of the peritoneum: a case report and review of the literature |
Q84082908 | Coexisting serous carcinoma of the endometrium and the fallopian tube |
Q91136543 | Colon Metastasis From Microscopic Serous Carcinoma of the Fallopian Tube Fimbria Mimicking a Primary Colon Cancer |
Q84782227 | Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology |
Q88274237 | Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma |
Q55452489 | Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. |
Q94549095 | Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma |
Q50457157 | Combined hepatoid and serous carcinoma of the uterine corpus: an undescribed phenomenon |
Q79767213 | Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread |
Q86588909 | Combined serous carcinoma and neuroendocrine carcinoma of the fallopian tube |
Q38856165 | Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital |
Q33751321 | Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight |
Q99233074 | Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma |
Q35694661 | Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients |
Q36231169 | Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis |
Q67947147 | Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma |
Q38179804 | Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary |
Q87486235 | Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma |
Q57477819 | Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma |
Q92361587 | Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination |
Q79825860 | Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma |
Q74645088 | Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma |
Q41671863 | Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin |
Q46846828 | Complete response to docetaxel and carboplatin combination chemotherapy for a stage IV uterine papillary serous carcinoma: a case report |
Q98514607 | Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma - an anachronism? |
Q71351423 | Computed tomography of uterine papillary serous carcinoma |
Q92433614 | Concurrent high-grade serous carcinoma and borderline tumor demonstrating different chemo-sensitivity |
Q72632226 | Concurrent ovarian serous carcinoma and osteogenesis imperfecta |
Q35580726 | Concurrent primary peritoneal low-grade serous carcinoma and endometrial high-grade serous carcinoma |
Q123915515 | Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival |
Q89178904 | Continuous successful re-aspirating a large obstructive pelvic cystic mass of low grade serous carcinoma after failed sclerotherapy |
Q92131983 | Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma |
Q38058666 | Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study |
Q89843390 | Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448] |
Q37232123 | Critical molecular abnormalities in high-grade serous carcinoma of the ovary |
Q88908047 | Culprit or Bystander? The Role of the Fallopian Tube in "Ovarian" High-Grade Serous Carcinoma |
Q53335378 | Cutaneous metastasis of uterine papillary serous carcinoma presenting as a solitary nodule on the umbilical area. |
Q69945905 | Cytologic features of endometrial papillary serous carcinoma |
Q74650130 | Cytologic features of villoglandular adenocarcinoma of the uterine cervix: comparison with typical endocervical adenocarcinoma with a villoglandular component and papillary serous carcinoma |
Q64083374 | Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma |
Q59809954 | Cytology of the fallopian tube: A screening model for high-grade serous carcinoma |
Q99239481 | Cytology positive pericardial effusion causing tamponade in patients with high grade serous carcinoma of the ovary |
Q50919255 | Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study. |
Q96349349 | Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma |
Q72253228 | Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma |
Q34595670 | Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma |
Q46314878 | Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion |
Q93168394 | Defining the molecular evolution of extrauterine high grade serous carcinoma |
Q64375199 | Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling |
Q80550856 | Depressed host immunity in a case of metachronous primary uterine papillary serous carcinoma and non-Hodgkin's lymphoma |
Q77228471 | Dermatomyositis and peritoneal papillary serous carcinoma |
Q100737232 | Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays |
Q34634149 | Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer |
Q88373802 | Diagnosis of primary peritoneal high-grade serous carcinoma in a man by cytology |
Q53286591 | Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. |
Q96228507 | Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma |
Q80352442 | Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps |
Q92524991 | Differential expression of immune related genes in high-grade ovarian serous carcinoma |
Q33233449 | Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma |
Q47749903 | Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage |
Q73965128 | Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum |
Q41557623 | Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. |
Q30446831 | Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin |
Q38283056 | Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach? |
Q35927368 | Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy |
Q34103978 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary |
Q34714574 | Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts |
Q36258125 | Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo |
Q34222070 | EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? |
Q38971615 | ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy |
Q88434848 | Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? |
Q46069036 | Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery |
Q45268051 | Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. |
Q53327771 | Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. |
Q38074214 | Early stage uterine serous carcinoma: management updates and genomic advances |
Q74159586 | Early uterine serous carcinoma: clonal origin of extrauterine disease |
Q53356684 | Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. |
Q72636529 | Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent |
Q88990761 | Efficacy of endocervical curettage and CA-125 measurement in endometrial serous carcinoma: A case series and literature review |
Q84155693 | Endobronchial metastasis from primary papillary serous carcinoma of the peritoneum |
Q34978084 | Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status |
Q26695612 | Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma |
Q43848072 | Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis |
Q41019634 | Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression |
Q41156485 | Endometrial papillary serous carcinoma: patterns of spread and treatment |
Q36003197 | Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. |
Q37017041 | Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies |
Q39035328 | Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up |
Q44498721 | Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers |
Q39208636 | Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients |
Q91707855 | Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma |
Q51746639 | Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. |
Q88347253 | Erratum: Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion |
Q39955890 | Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function |
Q68969086 | Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary |
Q74099950 | Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma |
Q80262379 | Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma |
Q34457825 | Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. |
Q72454022 | Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum |
Q40515254 | Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: case report |
Q77593219 | Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum |
Q47762675 | Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma |
Q41219933 | Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival |
Q48792129 | Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? |
Q92408734 | Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma |
Q44544392 | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium |
Q81475966 | Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival |
Q44053802 | Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival. |
Q86945717 | Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma |
Q37388641 | Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis |
Q98188493 | Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma |
Q96023330 | Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma |
Q39675522 | Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary |
Q88875414 | Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma |
Q73824541 | Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease |
Q37229341 | Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival |
Q48649110 | External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis. |
Q38964462 | Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study. |
Q46138913 | FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival |
Q39203802 | FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome |
Q94683666 | Fallopian tube abnormalities in uterine serous carcinoma |
Q88024397 | Fallopian tube high-grade serous carcinoma with intramucosal spread and presenting as a malignancy on pap smear |
Q44432679 | False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation |
Q77310541 | Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case |
Q36040635 | Fatal cardiac tamponade following cytoreductive surgery for serous carcinoma of the ovary |
Q53758785 | Fine needle aspiration cytology of a nodal low-grade serous neoplasm: a case report of low-grade serous carcinoma arising from a serous borderline tumour with cyto-histological correlation. |
Q40212189 | Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study |
Q57176040 | GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells |
Q91262242 | Gastrointestinal: Successful diagnosis of primary peritoneal serous carcinoma by endoscopic ultrasound-guided through-the-needle forceps biopsy |
Q37050667 | Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages |
Q34713009 | Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma |
Q37580229 | Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions |
Q38308209 | Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma |
Q73469351 | Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum |
Q38471333 | Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum |
Q42446598 | Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer |
Q64080187 | Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad |
Q44618222 | Glycodelin in ovarian serous carcinoma: association with differentiation and survival. |
Q79934949 | Grading ovarian serous carcinoma using a two-tier system |
Q33693203 | Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation |
Q52567521 | Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens. |
Q104129844 | HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting |
Q97561186 | HER2 Testing in Endometrial Serous Carcinoma |
Q39098938 | HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. |
Q83811112 | HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases |
Q83188780 | HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma |
Q84866516 | HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes |
Q45953122 | HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. |
Q41071376 | HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival |
Q80396741 | Her-2/neu overexpression and amplification in uterine papillary serous carcinoma |
Q35527141 | Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab |
Q83867495 | High grade serous carcinoma of the ovary with a yolk sac tumour component in a postmenopausal woman: report of an extremely rare phenomenon |
Q38720158 | High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum |
Q91871554 | High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer |
Q100433330 | High-Grade Serous Carcinoma of the Fallopian Tube |
Q35210293 | High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma |
Q91598628 | High-grade Pelvic Serous Carcinoma Within the Fallopian Tube Lumen: Real or Artifact? |
Q51753726 | High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. |
Q47150076 | High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism |
Q47811275 | High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman |
Q97532129 | High-grade serous carcinoma of fallopian tube with yolk sac tumor differentiation in a postmenopausal patient |
Q37553367 | High-grade serous carcinoma of the ovary |
Q38687061 | High-grade serous carcinoma of tubo-ovarian origin: recent developments. |
Q55347281 | High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis. |
Q60910235 | High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature |
Q91228892 | Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results |
Q35510378 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum |
Q97691132 | Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study |
Q91653197 | Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression |
Q37286791 | Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer |
Q53470669 | IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. |
Q73377447 | Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum |
Q73622085 | Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum |
Q53247084 | Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution. |
Q97592738 | Identification of aberrantly expressed long non-coding RNAs in ovarian high-grade serous carcinoma cells |
Q34393919 | Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. |
Q96952577 | Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice |
Q85493415 | Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma |
Q100425897 | Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma |
Q96581801 | IgG4-Related Disease with Ascites: Report of a Case Simulating Primary Peritoneal Papillary Serous Carcinoma |
Q95273459 | Imaging features of primary peritoneal serous carcinoma: A case report |
Q46948132 | Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful |
Q95591382 | Immunohistochemical c-kit expression in uterine serous carcinoma tissue |
Q82723168 | Immunohistochemical characterization of endocervical papillary serous carcinoma |
Q87556647 | Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma |
Q80506055 | Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma |
Q43997124 | Immunophenotyping of serous carcinoma of the female genital tract |
Q89421055 | Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma |
Q35947034 | Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. |
Q38855844 | Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus |
Q81297998 | Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma |
Q36750622 | Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. |
Q34432555 | Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy |
Q48345561 | Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks |
Q89601813 | Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation |
Q88434551 | Incidental Small Ovarian Surface Serous Carcinoma With Miliary Abdominal Seeding During Robotic-Assisted Total Hysterectomy |
Q41678534 | Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series |
Q33986711 | Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival |
Q92332337 | Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database |
Q77789601 | Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma |
Q89239902 | Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer |
Q39011970 | Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model |
Q37148431 | Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway |
Q94459634 | Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla-Site of Origin of Serous Carcinoma of the Ovary |
Q33761023 | Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria |
Q52881563 | Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway. |
Q53337533 | Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. |
Q53009456 | Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. |
Q81420853 | Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study |
Q51786033 | Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. |
Q93335726 | Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis |
Q90255806 | Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study |
Q72253272 | Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC) |
Q37146082 | Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes |
Q35104225 | Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency |
Q91990276 | In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma |
Q40170913 | Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? |
Q74715857 | Is micropapillary serous carcinoma for real? |
Q74033619 | Is papillary serous carcinoma of the peritoneum (PSCP) a multifocal disease? |
Q53082153 | Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. |
Q48685364 | Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40:860-7. |
Q98902335 | KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma |
Q33893010 | KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma |
Q57791800 | Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis |
Q37349904 | Large cell neuroendocrine carcinoma of the ovary associated with serous carcinoma with mucin production: a case report and literature review. |
Q39042556 | Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. |
Q35607666 | Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum |
Q47218847 | Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum |
Q85190056 | Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma |
Q74525507 | Long-term survival of a patient with primary papillary serous carcinoma of the peritoneum treated by subtotal peritonectomy plus intraoperative chemohyperthermia |
Q47320277 | Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum |
Q35132433 | Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma |
Q80456258 | Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma |
Q42365263 | Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium |
Q37452286 | Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival |
Q104136011 | Loss of tubal ciliated cells as a risk for "ovarian" or pelvic serous carcinoma |
Q96230943 | Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa |
Q33527712 | Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary |
Q53278948 | Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. |
Q50856533 | Low-grade serous carcinoma of the ovary or peritoneum. |
Q38514737 | Low-grade serous carcinoma: molecular features and contemporary treatment strategies |
Q38109432 | Low-grade serous carcinoma: new concepts and emerging therapies. |
Q91288786 | Lymphatic Invasion in the Fallopian Tube is a Late Event in the Progression of Pelvic Serous Carcinoma and Correlates With Distant Metastasis |
Q37316711 | MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma |
Q81597613 | MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium |
Q91557739 | MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor |
Q96637714 | Magnetic resonance imaging findings of extrauterine high-grade serous carcinoma based on new pathologic criteria for primary site assignment |
Q50115349 | Malignant Endometrial Polyps in Uterine Serous Carcinoma: The Prognostic Value of Polyp Size and Lymphovascular Invasion |
Q80456304 | Malignant mixed müllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report |
Q74310041 | Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases |
Q77932350 | Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium |
Q95382817 | Masquerading as Sigmoid Adenocarcinoma: A Unique Presentation of High-Grade Serous Carcinoma Arising from Endometriosis |
Q92643955 | Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma |
Q91851414 | Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it |
Q91648665 | Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment |
Q58789603 | Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
Q92321835 | Metastatic Carcinoma of Endometrium from Primary Ovarian Serous Carcinoma Mimicking a Primary Uterine Tumour |
Q62112710 | Metastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case Report |
Q48164105 | Metastatic Ovarian Serous Carcinoma of the Breast. |
Q57094535 | Metastatic Squamous Cell Carcinoma versus Primary High Grade Serous Carcinoma of the Ovary |
Q42796773 | Metastatic ovarian papillary serous carcinoma to the breast: Diagnosis and pitfalls |
Q90465720 | Metastatic peripancreatic lymph nodes resection during primary debulking surgery for primary peritoneal serous carcinoma |
Q37876750 | Metastatic serous carcinoma of the testis: a case report and review of the literature. |
Q48197150 | Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-Report of two cases and literature review |
Q46234989 | Metastatic uterine papillary serous carcinoma to the pericardium |
Q81669706 | Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases |
Q28486318 | Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners |
Q98164275 | MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma |
Q92858992 | MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma |
Q42669113 | Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas |
Q45100967 | Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors |
Q73451474 | Micropapillary serous carcinoma of the ovary: a report of three cases |
Q74219935 | Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53 |
Q34072369 | Micropapillary serous carcinoma of the ovary: case report and review of literature |
Q74455494 | Micropapillary serous carcinoma of the ovary: cytomorphologic characteristics in peritoneal/pelvic washings |
Q72850970 | Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma |
Q50049913 | Microsatellite instability-high endocervical serous carcinoma manifesting as pulmonary thromboembolism: A case report and review of the literature. |
Q36553567 | Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases |
Q84972872 | Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases |
Q80608581 | Minimal uterine serous carcinoma: a clinicopathological study of 40 cases |
Q36762035 | Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis |
Q33937418 | Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation |
Q61840587 | Mixed endometrioid and serous carcinoma developing in abdominal wall endometriosis following Cesarean section |
Q92120418 | Mixed large and small cell neuroendocrine carcinoma of the endometrium with serous carcinoma: A case report and literature review |
Q81227523 | Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases |
Q80421554 | Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin |
Q37119791 | Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms |
Q36416465 | Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study |
Q104562625 | Molecular analysis of a rare case of low-grade primary peritoneal serous carcinoma in a male |
Q34682062 | Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum |
Q47979918 | Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations |
Q37197308 | Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium |
Q30430198 | Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma |
Q91758702 | Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology |
Q48541433 | Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. |
Q36037099 | Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma |
Q69879973 | Multiple focal extraovarian serous carcinoma |
Q69782356 | Multiple focal extraovarian serous carcinoma; three case reports |
Q83698217 | Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma |
Q90317700 | Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions |
Q34729698 | Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum |
Q71215858 | Neoadjuvant chemotherapy in uterine papillary serous carcinoma |
Q38965974 | Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo |
Q34543315 | New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research |
Q77420326 | No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report |
Q68016672 | Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels |
Q46517040 | Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia |
Q47888032 | Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases |
Q95719057 | Noninvasive papillary serous carcinoma of the endometrium |
Q50658626 | Normal-sized ovarian papillary serous carcinoma: a case report |
Q53093440 | Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. |
Q57171344 | ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro |
Q87752008 | Occult serous carcinoma of fallopian tube presenting as supraclavicular lymphadenopathy |
Q79467462 | Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma |
Q39119683 | Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). |
Q34473693 | Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. |
Q46673327 | Optimal surgical debulking in uterine papillary serous carcinoma affects survival |
Q26852698 | Origin and molecular pathogenesis of ovarian high-grade serous carcinoma |
Q34728110 | Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). |
Q40554058 | Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy |
Q38300943 | Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy |
Q79931185 | Outcomes in surgical stage I uterine papillary serous carcinoma |
Q58763140 | Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience |
Q64053341 | Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708) |
Q39660398 | Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system |
Q92086542 | Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes |
Q47144220 | Ovarian Large Cell Neuroendocrine Carcinoma Associated with Serous Carcinoma: Correlation of Pathology with MR Imaging |
Q104479678 | Ovarian Seromucinous Carcinoma With Extensive Bilateral Fallopian Tubes Metastases by the Low-grade Serous Carcinoma Component Mimicking Serous Tubal Intraepithelial Carcinoma: Case Presentation and Literature Review |
Q87108036 | Ovarian Yolk Sac Tumor With High-Grade Serous Carcinoma in a 62-Year-Old Woman |
Q35732549 | Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor |
Q38007297 | Ovarian low-grade serous carcinoma: a comprehensive update |
Q40762738 | Ovarian lymphoma and serous carcinoma of low malignant potential arising in the same ovary. A case report with literature review of 14 primary ovarian lymphomas. |
Q46008296 | Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern. |
Q92867921 | Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature |
Q57764870 | Ovarian serous carcinoma presenting with mediastinal lymphadenopathy 20 months before the intraabdominal mass: Role of immunohistochemistry |
Q85055443 | Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression |
Q44548482 | Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum |
Q73544510 | Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma |
Q71203864 | Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease |
Q94564706 | PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma |
Q40389999 | PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors |
Q43539364 | PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma |
Q30434644 | PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma |
Q89345179 | Papillary Serous Carcinoma of the Peritoneum Mimicking an Ovarian Cyst in Pregnancy |
Q79969294 | Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma |
Q82539042 | Papillary serous carcinoma arising in abdominal wall endometriosis treated with neoadjuvant chemotherapy and surgery |
Q36769540 | Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma |
Q84104948 | Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier |
Q81670753 | Papillary serous carcinoma of ovarian type of the testis with borderline differentiation |
Q34468842 | Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors. |
Q53514541 | Papillary serous carcinoma of peritoneum: presentation of 2 cases. |
Q81327989 | Papillary serous carcinoma of the broad ligament: a rare case report |
Q41813547 | Papillary serous carcinoma of the cervix mixed with squamous cells: A report of the first case |
Q77362148 | Papillary serous carcinoma of the cervix: ultrasonographic findings |
Q33690133 | Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment |
Q68690263 | Papillary serous carcinoma of the ovary with squamous differentiation |
Q80836150 | Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study |
Q72693859 | Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma |
Q41086283 | Papillary serous carcinoma of the peritoneum |
Q44099816 | Papillary serous carcinoma of the peritoneum |
Q38458052 | Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma |
Q68018399 | Papillary serous carcinoma of the peritoneum following endometrial cancer |
Q50905113 | Papillary serous carcinoma of the peritoneum in a man: a case report. |
Q71067204 | Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study |
Q79739656 | Papillary serous carcinoma of the peritoneum with paraaortic lymph node metastasis despite minimal intraperitoneal involvement: a case report |
Q38134731 | Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy |
Q74033590 | Papillary serous carcinoma of the peritoneum: analysis of clonality of peritoneal tumors |
Q72694363 | Papillary serous carcinoma of the retroperitoneum |
Q73458096 | Papillary serous carcinoma of the tunica vaginalis testis |
Q37673727 | Papillary serous carcinoma of the uterine cervix with lung metastasis |
Q74015315 | Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases |
Q71224613 | Papillary serous carcinoma of the uterus arising in an adenomyoma |
Q77323324 | Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma |
Q68944031 | Papillary serous carcinoma with basophilic cytoplasmic granules |
Q83878105 | Papillary syncytial metaplasia associated with endometrial breakdown exhibits an immunophenotype that overlaps with uterine serous carcinoma |
Q72053828 | Paraneoplastic Hypercalcemia Associated with Uterine Papillary Serous Carcinoma |
Q33561544 | Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin |
Q90399148 | Pathogenesis and Clinical Management of Uterine Serous Carcinoma |
Q34402523 | Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma |
Q81222569 | Pathologic quiz case: a 54-year-old woman with bilateral pelvic masses. Well-differentiated papillary serous carcinoma arising in serous adenofibroma of borderline malignancy |
Q92225127 | Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data |
Q88395436 | Patient with Proteus syndrome and paratesticular ovarian-type papillary serous carcinoma |
Q85112344 | Patterns of Low-grade Serous Carcinoma With Emphasis on the Nonepithelial-lined Spaces Pattern of Invasion and the Disorganized Orphan Papillae |
Q41435144 | Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database |
Q46263824 | Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy |
Q58088279 | Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma |
Q34829897 | Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin |
Q80488783 | Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report |
Q51559692 | Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. |
Q72130957 | Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors |
Q70496431 | Peritoneal papillary serous carcinoma in a woman with a history of utero DES exposure |
Q69587609 | Peritoneal papillary serous carcinoma with long-term survival |
Q72034942 | Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease |
Q64969180 | Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma. |
Q53174208 | Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. |
Q92952211 | Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma |
Q86194171 | Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case |
Q33377350 | Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). |
Q50481932 | Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. |
Q86145706 | Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients |
Q96950416 | Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database |
Q86708409 | Population-based treatment and outcomes of Stage I uterine serous carcinoma |
Q44165705 | Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC). |
Q28072095 | Practical issues in the diagnosis of serous carcinoma of the endometrium |
Q86046480 | Precursor lesions and prognostic factors in primary peritoneal serous carcinoma |
Q37399709 | Precursors to pelvic serous carcinoma and their clinical implications |
Q34552129 | Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma |
Q84734401 | Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients |
Q94518598 | Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology |
Q91634050 | Primary Peritoneal Low-grade Serous Carcinoma in a Patient With Lynch Syndrome: A Case Report |
Q93245955 | Primary Peritoneal Serous Carcinoma Detected by Abnormal Cervical Smear: a Case Report |
Q40182860 | Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity |
Q85588429 | Primary high-grade serous carcinoma arising in the urethra or urethral diverticulum: a report of 2 cases of an extremely rare phenomenon |
Q98906043 | Primary mixed large cell neuroendocrine and high grade serous carcinoma of the endometrium |
Q37231008 | Primary papillary serous carcinoma of the peritoneum diagnosed by video-assisted thoracoscopic surgery: report of a case |
Q73998284 | Primary papillary serous carcinoma of the peritoneum in a man |
Q73917710 | Primary papillary serous carcinoma of the peritoneum: CT-pathologic correlation |
Q67925647 | Primary papillary serous carcinoma of the peritoneum: a case of complete remission of bulky peritoneal disease after chemotherapy |
Q35877546 | Primary papillary serous carcinoma of the peritoneum: four cases and review of computed tomography findings |
Q36787135 | Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry |
Q45773745 | Primary peritoneal low-grade serous carcinoma forming a mass in the colon mimicking a colonic primary carcinoma: a case report |
Q83488841 | Primary peritoneal serous carcinoma presenting as inflammatory breast cancer |
Q44556615 | Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. |
Q37379544 | Primary peritoneal serous carcinoma with signet ring cells |
Q36954614 | Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature |
Q36305409 | Primary peritoneal serous carcinoma: a clinicopathological and immunohistochemical study of six cases |
Q34032865 | Primary peritoneal serous carcinoma: a rare case and palliative approach |
Q71447480 | Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma |
Q37052072 | Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report |
Q68044750 | Primary serous carcinoma of the female peritoneum. Report of a case with a re-examination of a histogenetic problem based on the use of a specific antimesothelial-cell antibody |
Q80387943 | Primary serous carcinoma of the peritoneum producing granulocyte colony-stimulating factor |
Q50236868 | Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide |
Q67555431 | Primary, papillary serous carcinoma of the peritoneum; a report of experiences |
Q36592537 | Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma |
Q34345071 | Prognosis for papillary serous carcinoma of the endometrium after surgical staging |
Q37975098 | Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review |
Q84689911 | Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma |
Q80230332 | Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma |
Q55261133 | Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. |
Q93057055 | Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma |
Q27853285 | Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma |
Q80550802 | Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma |
Q81333205 | Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary |
Q58595581 | Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the coeur cohort |
Q38306666 | Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions |
Q81535180 | Proliferating multicentric reticulohistiocytosis associated with papillary serous carcinoma of the endometrium |
Q94491524 | Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma |
Q86746941 | Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma |
Q68619006 | Psammoma bodies in serous carcinoma of the ovary. A prognostic study |
Q44052187 | Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma |
Q40524250 | Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011. |
Q52605005 | Radiation-associated Angiosarcoma Mimicking Fallopian Tube High-grade Serous Carcinoma in a Woman With De Novo Li-Fraumeni Syndrome. |
Q78056451 | Rapid death following papillary serous carcinoma of the endometrium without myometrial invasion |
Q37295240 | Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact? |
Q53419279 | Rare case of coexistence of primary ovarian carcinoid in mature teratoma with primary serous carcinoma in second ovary--a case report. |
Q92992169 | Rare case of paraneoplastic cerebellar degeneration secondary to high-grade serous carcinoma of tubo-ovarian origin |
Q40729497 | Rare form of extraovarian primary peritoneal papillary serous carcinoma with solitary cystic lesion mimicking a liver tumor; report of a case |
Q30250107 | Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence |
Q72297401 | Re: Uterine papillary serous carcinoma: patterns of metastatic spread |
Q84869461 | Reactive tubal epithelium mimicking Mullerian serous carcinoma: pitfalls in the evaluation of pelvic wash specimens |
Q34201837 | Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. |
Q74715917 | Recurrent micropapillary serous ovarian carcinoma |
Q42594882 | Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine |
Q92003108 | Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report |
Q92443807 | Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre |
Q37524030 | Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). |
Q73133753 | Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report |
Q82446554 | Retroperitoneal tuberculosis in a patient with uterine papillary serous carcinoma |
Q37502654 | Rhabdomyosarcoma arising in a mature cystic teratoma with contralateral serous carcinoma: case report and review of the literature |
Q39886748 | Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation |
Q91798983 | Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma |
Q98509041 | S100A4/non-muscle myosin IIA/p53 axis contributes to aggressive features in ovarian high-grade serous carcinoma |
Q92572537 | SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma |
Q50020012 | STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube |
Q38766901 | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression |
Q55456064 | Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. |
Q89879980 | Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding |
Q90094958 | Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma |
Q36768921 | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study |
Q91327127 | Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma |
Q45980545 | Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. |
Q48515431 | Serous Carcinoma of the Uterine Cervix, an Extremely Rare Aggressive Entity: A Literature Review. |
Q81420801 | Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management |
Q47737327 | Serous carcinoma arising from adenomyosis |
Q36969096 | Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases |
Q73155676 | Serous carcinoma arising in an adenofibroma of the endometrium |
Q43421930 | Serous carcinoma arising in endometrial polyps: clinicopathologic study of 4 cases |
Q44773054 | Serous carcinoma in endometrial polyps |
Q98946974 | Serous carcinoma of a prolapsed fallopian tube: A rare cause of a vaginal apex mass |
Q37146313 | Serous carcinoma of endometrium in combination with neuroendocrine small-cell: A case report and literature review |
Q36523858 | Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types |
Q82739434 | Serous carcinoma of the fallopian tube presenting as axillary lymphadenopathy |
Q81092327 | Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall |
Q38125072 | Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review |
Q80464993 | Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy |
Q70007943 | Serous carcinoma of the ovary: CT identification of metastatic calcified implants |
Q68583258 | Serous carcinoma of the ovary: value of computed tomography in detection of calcified pleural and pulmonary metastatic implants |
Q45733721 | Serous carcinoma of the peritoneum after oophorectomy |
Q39349153 | Serous carcinoma of the testicle and paratesticular tissue: Case Report and Literature Review |
Q90896657 | Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs |
Q46773197 | Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation |
Q30461903 | Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma |
Q41445288 | Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer). |
Q53140410 | Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development. |
Q37125079 | Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention |
Q73258220 | Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma |
Q91608882 | Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma |
Q46380307 | Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. |
Q53677145 | Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence? |
Q46988991 | Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis |
Q80163837 | Skin metastases revealing a bilateral ovarian invasive micropapillary serous carcinoma |
Q60914787 | Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube |
Q31123493 | Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma |
Q54054684 | Sonographic depiction of non-palpable uterine papillary serous carcinoma metastasis embedded within the abdominal wall. |
Q51138602 | Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion. |
Q37965359 | Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival |
Q73981687 | Stage IA uterine serous carcinoma: a study of 13 cases |
Q83135150 | Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes |
Q91718293 | Stage III uterine serous carcinoma: modern trends in multimodality treatment |
Q53092471 | Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. |
Q33743091 | Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy |
Q98204669 | Stemness in high-grade serous carcinoma of tubo-ovarian origin causes multiple immunohistochemical pitfalls: a case report |
Q64083343 | Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma |
Q33366370 | Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data |
Q91025908 | Successful multidisciplinary treatment of uterine serous carcinoma in a patient who had previously undergone renal transplantation |
Q92433890 | Successful radiotherapy for endometrial serous carcinoma with local repeated recurrence |
Q96642204 | Superior vena cava syndrome associated with uterine serous carcinoma |
Q89868575 | Surprise Lymph Node Histology in a Patient with Ovarian Serous Carcinoma |
Q48922677 | Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study |
Q98514592 | Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma |
Q38967788 | Synchronous Low-grade Appendiceal Mucinous Neoplasm and Primary Peritoneal Low-grade Serous Carcinoma: A First Description of These 2 Neoplasms Presenting Together as Suspected Peritoneal Carcinomatosis. |
Q51214003 | Synchronous carcinosarcoma uterus and primary serous carcinoma of bilateral fallopian tubes: a case report. |
Q34491116 | Synchronous occurrence of endometrial stromal nodule with papillary serous carcinoma of ovary: report of a case and brief review of literature |
Q46451745 | Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor |
Q61808108 | Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations |
Q71544451 | Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation |
Q39123683 | Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study |
Q93126756 | Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing |
Q34998509 | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo |
Q47350535 | TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern. |
Q93021925 | Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern |
Q37699264 | Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer |
Q60924976 | Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management |
Q64094681 | Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation |
Q51609396 | Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. |
Q34729807 | Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo |
Q100993037 | Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue |
Q79862089 | Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum |
Q90301593 | The "Far Left" of the Morphologic Spectrum of Ovarian High-Grade Serous Carcinoma: Case Report of a Purely Noninvasive High-Grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor |
Q40253367 | The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary |
Q40500136 | The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians |
Q69387829 | The biologic behavior of low-grade papillary serous carcinoma of the ovary |
Q36624703 | The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma |
Q34179788 | The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression |
Q89074328 | The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum |
Q41747755 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions |
Q46595130 | The cytomorphology of papillary serous carcinoma of the endometrium in cervical smears |
Q36994615 | The development of papillary serous carcinoma of the peritoneum subsequent to endometrial carcinoma: a case report and review of the literature |
Q79772649 | The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma |
Q79080812 | The effect of cyclooxygenase‐2 expression on tumor vascularity in advanced stage ovarian serous carcinoma |
Q48774780 | The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). |
Q84635438 | The evolving pathogenesis model of high-grade pelvic serous carcinoma |
Q82941868 | The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma |
Q90021710 | The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma |
Q73459314 | The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways |
Q100497506 | The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma |
Q81872426 | The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma |
Q36475131 | The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. |
Q37850052 | The impact of race on survival in uterine serous carcinoma: a hospital-based study |
Q58073798 | The importance of chemotherapy and radiation in uterine papillary serous carcinoma |
Q86702474 | The importance of surgical staging in women with uterine serous carcinoma: experience in a single institution reveals a survival benefit |
Q38110044 | The life and times of low-grade serous carcinoma of the ovary |
Q98574953 | The methylomic landscape of fallopian tube lesions associated with ovarian high-grade serous carcinoma |
Q80556503 | The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma |
Q100473017 | The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma |
Q44239150 | The prognosis in early endometrial carcinoma. The importance of uterine papillary serous carcinoma (UPSC), age, FIGO grade and nuclear grade |
Q38427509 | The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary |
Q47111746 | The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients |
Q73691527 | The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma |
Q97691128 | The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance |
Q90090414 | The role of omentectomy in the surgical treatment of uterine serous carcinoma |
Q35840405 | The role of optimal debulking in advanced stage serous carcinoma of the uterus |
Q38540739 | The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters |
Q73591470 | The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing? |
Q78038994 | The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma |
Q69722257 | Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report |
Q53539806 | Three-dimensional power doppler ultrasound is useful to monitor the response to treatment in a patient with primary papillary serous carcinoma of the peritoneum. |
Q95499783 | Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site |
Q44522454 | Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice |
Q38047180 | Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. |
Q104739133 | Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis |
Q51814615 | Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. |
Q34293815 | Treatment of uterine papillary serous carcinoma with paclitaxel |
Q36412970 | Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel |
Q40179085 | Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study |
Q71856659 | Tubal (serous) carcinoma of the endometrium |
Q64063717 | Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study |
Q84436616 | Tubal origin of 'ovarian' low-grade serous carcinoma |
Q36169161 | Tuberous sclerosis complex associated with papillary serous carcinoma of the peritoneum, lymphangioleiomyomatosis, and angiomyolipoma |
Q90611516 | Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles |
Q102375662 | Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements |
Q91541829 | Tumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma |
Q91474691 | Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma |
Q81377645 | Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma |
Q84483062 | Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma |
Q71355889 | Ultrastructure of papillary serous carcinoma of the endometrium |
Q88138370 | Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor |
Q90156646 | Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC |
Q93022363 | Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients |
Q38640219 | Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases |
Q54262262 | Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC) |
Q70789016 | Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases |
Q35607764 | Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases |
Q74739391 | Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study |
Q35042959 | Uterine papillary serous carcinoma after pelvic radiation therapy for cancer of the cervix |
Q36729547 | Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix |
Q53449426 | Uterine papillary serous carcinoma evolves via a p53-driven pathway. |
Q73591125 | Uterine papillary serous carcinoma following radiation therapy for carcinoma of cervix: a case report |
Q72361873 | Uterine papillary serous carcinoma in a 32-year-old with Turner's syndrome |
Q85948087 | Uterine papillary serous carcinoma metastatic to the choroid |
Q40668211 | Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary? |
Q34192554 | Uterine papillary serous carcinoma presenting as distant lymph node metastasis |
Q72195285 | Uterine papillary serous carcinoma revisited |
Q40671362 | Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide |
Q43989674 | Uterine papillary serous carcinoma with high levels of serum carcinoembryonic antigen. Response to combination chemotherapy |
Q40342686 | Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma |
Q83857347 | Uterine papillary serous carcinoma: a new paradigm for treatment? |
Q36787306 | Uterine papillary serous carcinoma: a review |
Q68203357 | Uterine papillary serous carcinoma: a review |
Q67975840 | Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma |
Q34283694 | Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy |
Q37642512 | Uterine papillary serous carcinoma: epidemiology, pathogenesis and management |
Q74507000 | Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients |
Q36412974 | Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. |
Q37582977 | Uterine papillary serous carcinoma: patterns of failure and survival. |
Q72195288 | Uterine papillary serous carcinoma: patterns of metastatic spread |
Q37301327 | Uterine papillary serous carcinoma: state of the state |
Q74714458 | Uterine papillary serous carcinoma: study of 19 cases |
Q81088714 | Uterine papillary serous carcinoma: what have we learned over the past quarter century? |
Q44619903 | Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy |
Q101451083 | Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies |
Q88087857 | Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy |
Q80268165 | Uterine serous carcinoma: a comparison of therapy for advanced-stage disease |
Q47311133 | Uterine serous carcinoma: a historic evaluation of therapy |
Q30422098 | Uterine serous carcinoma: increased familial risk for lynch-associated malignancies |
Q37724181 | Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary |
Q39997968 | Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma. |
Q81679477 | Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma |
Q50663650 | VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. |
Q36388827 | Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update |
Q81223439 | Virchow's node as a first manifestation of ovarian serous carcinoma: case report |
Q79836060 | WT-1 and serous carcinoma |
Q62897746 | WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma |
Q81614735 | WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis |
Q84690197 | WT1, p53 and hormone receptor expression in uterine serous carcinoma |
Q36685324 | YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. |
Q92885208 | Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component |
Q79842323 | [Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma] |
Q83415067 | [Clinical significance of two-tier grading system of ovarian serous carcinoma] |
Q90257392 | [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma] |
Q81831674 | [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma] |
Q54458348 | [Conceptual issues and diagnostic updates on endometrial serous carcinoma and its precursor]. |
Q104564820 | [Diagnosis, treatment and prognosis of uterine serous carcinoma] |
Q82986986 | [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma] |
Q83249807 | [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma] |
Q84037597 | [II. Endometrial neoplasms 1. Papillary serous carcinoma] |
Q95520094 | [Pathologic features of fallopian tubal fimbriae in patients with endometrial serous carcinoma] |
Q83142551 | [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case] |
Q73065962 | [Peritoneal papillary serous carcinoma: clinical report] |
Q85621791 | [Peritoneal tumor pathology: case no. 7: poor-differentiated primary peritoneal high-grade serous carcinoma] |
Q89941501 | [Serous Carcinoma of the Peritoneum with Metastases to the Breast and Axillary Lymph Nodes] |
Q71400529 | [Uterine papillary serous carcinoma and papillary endometrial carcinoma: analysis of clinical biological behaviors of 56 cases] |
Q82292474 | [Uterine papillary serous carcinoma: report of a case] |
Q84512866 | [Uterine papillary serous carcinoma] |
Q91039509 | [Uterine serous carcinoma accompany with serous endometrial intraepithelial carcinoma and papillary proliferation of the endometrium: report of a case] |
Q73153525 | beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma |
Q39145559 | miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. |
Q73834155 | p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma |
Q82236202 | p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy |
Q81119402 | p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium |
Q35765367 | p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. |
Q73598499 | ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum |
Q98386393 | xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma |
Serous carcinoma | wikipedia |
Search more.